BeyondSpring vs SELLAS Life Sciences
BYSI and SLS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BYSI and SLS compare
SELLAS Life Sciences scores higher on the StockData Score (7 against 4 for BeyondSpring), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BYSI | SLS |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.7B |
| Share price | $0.644 | $8.42 |
| Change, 1 year | −66.6% | 461% |
| Change, 5 years | −95.1% | 20.1% |
| Beta (5Y) | 0.54 | 1.49 |
| Employees | 44 | 13 |
| StockData Score | ||
| Total score | 4 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 12.4× |
| Profitability | ||
| Return on equity | – | −39.6% |
| Return on invested capital | – | −85609% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.70 | 18.83 (better) |
| Altman Z-score | – | 129.54 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 14.7% | 36.5% |
| Held by insiders | 31.2% | 1.8% |
| Insider net buying, 12 months | $0 | $0 |
| Short interest, % of float | 8.0% | 28.8% |
Go deeper
- BYSI stock overview
- BYSI income statement
- BYSI valuation and score
- SLS stock overview
- SLS income statement
- SLS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.